Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Stock-based compensation expense, net of tax by Year
Stock-based compensation expense, net of tax ($M) ($M)
Vertex Pharmaceuticals Stock-based compensation expense, net of tax: $557M in FY2025, up 24.7% from a year earlier. That is the highest of the 9 years on record here.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-13) ↗
Reported in Form 10-Q / 10-K Note (Stock-based Compensation).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Stock-based compensation expense, net of tax ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 557 | +24.7% | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 447 | +8.0% | Form 10-K (filed 2026-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 414 | +19.2% | Form 10-K (filed 2026-02-13) ↗ |
| FY2022 | Dec 31, 2022 | 347 | -3.2% | Form 10-K (filed 2025-02-13) ↗ |
| FY2021 | Dec 31, 2021 | 359 | +26.9% | Form 10-K (filed 2024-02-15) ↗ |
| FY2020 | Dec 31, 2020 | 283 | +19.6% | Form 10-K (filed 2023-02-10) ↗ |
| FY2019 | Dec 31, 2019 | 236 | -27.3% | Form 10-K (filed 2022-02-09) ↗ |
| FY2018 | Dec 31, 2018 | 325 | +10.9% | Form 10-K (filed 2021-02-11) ↗ |
| FY2017 | Dec 31, 2017 | 293 | – | Form 10-K (filed 2020-02-13) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Stock-based compensation expense, net of tax ($M), annual FY2017–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/sbc-net-tax
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.